TipRanks on MSN

Septerna initiated with a buy at Truist

Truist initiated coverage of Septerna (SEPN) with a Buy rating and $34 price target The firm says the company’s SEP-631 is in Phase 1 for chronic ...

NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...